Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Inhibikase Therapeutics, Inc. - Common Stock (NQ:IKT)

1.700 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Inhibikase Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Dr. Milton Werner, CEO of Inhibikase Therapeutics, Inc. is Featured in an Interview With SmallCapsDaily
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Nasdaq Stocks Above $2 to Watch Now! LVTX, INBS, IKT, PCSA, DYAI
Via AB Newswire
Topics Retirement
News headline image
Inhibikase Therapeutics Announces Publication Highlighting Results from its Phase 1 Studies with Risvodetinib
From Inhibikase Therapeutics
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
Inhibikase Therapeutics: Q3 Earnings Insights ↗
 
Via Benzinga
News headline image
Earnings Preview For Inhibikase Therapeutics ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
Inhibikase Therapeutics Announces Planned Retirement of Chief Financial Officer Joseph Frattaroli
Joseph Frattaroli to retire at end of 1Q24; Garth Lees-Rolfe, Vice-President of Finance, to be promoted to Chief Financial Officer 
From Inhibikase Therapeutics
Via GlobeNewswire
News headline image
Why Dermata Therapeutics Shares Are Trading Higher By Over 57%; Here Are 20 Stocks Moving Premarket ↗
Shares of Dermata Therapeutics, Inc. (NASDAQ: DRMA) rose sharply in pre-market trading after the company announced the issuance of a new patent in Japan for its DMT410 program for the treatment of... 
Via Benzinga
Topics Intellectual Property
News headline image
Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs
From Inhibikase Therapeutics
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
Why bluebird bio Shares Are Trading Higher? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
Shares of bluebird bio, Inc. (NASDAQ: BLUE) rose sharply during Monday’s session after the company presented updated data from its gene therapy program in transfusion-dependent beta-thalassemia at the... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
Inhibikase Therapeutics Granted Pre-NDA Meeting with the FDA for IkT-001Pro
From Inhibikase Therapeutics
Via GlobeNewswire
News headline image
Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Period Activity
Company to host conference call on Wednesday, November 15, 2023 at 8:00 a.m. ET 
From Inhibikase Therapeutics
Via GlobeNewswire
News headline image
Correcting & Replacing -- Inhibikase Therapeutics to Report Third Quarter Financial Results on November 14, 2023
From Inhibikase Therapeutics
Via GlobeNewswire
News headline image
Inhibikase Therapeutics to Report Second Quarter Financial Results on November 14, 2023
From Inhibikase Therapeutics
Via GlobeNewswire
News headline image
Inhibikase Therapeutics Highlights Unblinded Functional Analysis from the 201 Trial of Risvodetinib in Untreated Parkinson’s Disease and Provides Update on Ongoing Enrollment
From Inhibikase Therapeutics
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
Why Cal-Maine Foods Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
Gainers Gaucho Group Holdings, Inc. (NASDAQ: VINO) jumped 95.2% to $3.7280. Gaucho Group is planning to list two of its retail properties in Argentina, in San Rafael and Cordoba, for sale, priced at $2... 
Via Benzinga
News headline image
Inhibikase Therapeutics Receives FDA Orphan Drug Designation for Risvodetinib for the Treatment of Multiple System Atrophy
From Inhibikase Therapeutics
Via GlobeNewswire
News headline image
Why Fresh Tracks Therapeutics Shares Are Trading Higher By Around 53%; Here Are 20 Stocks Moving Premarket ↗
Gainers TransCode Therapeutics, Inc. (NASDAQ: RNAZ) shares rose 70.2% to $0.8937 in pre-market trading after falling 10% on Tuesday. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
Why Avalo Therapeutics Shares Are Trading Higher By 25%; Here Are 20 Stocks Moving Premarket ↗
Gainers 
Via Benzinga
News headline image
Earnings Scheduled For August 14, 2023 ↗
Companies Reporting Before The Bell • Safe & Green Holdings (NASDAQ:SGBX) is likely to report quarterly loss at $0.23 per share on revenue of $6.88 million. 
Via Benzinga
News headline image
Inhibikase Therapeutics: A Novel And Promising Approach To Neurodegeneration And Oncology ↗
IKT's heavily discounted valuation provides a compelling risk/reward given the ability to establish both safety and efficacy in Parkinson’s disease let alone any progress in oncology. 
Via Talk Markets
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.